AstraZeneca

107 articles with AstraZeneca

• AstraZeneca France Using Questionmark Online Assessments to Train On-Field Sales Teams

  11/24/2020

  The French subsidiary of AstraZeneca, the leading global pharmaceutical company, is assessing the scientific knowledge of its on-field sales team using Questionmark’s enterprise-grade assessment platform . Ensuring those teams are up to date on the latest science is a priority for the bu

• Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development

  11/23/2020

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH)

• IMFINZI® (durvalumab) Approved In The US For Less-Frequent, Fixed-Dose Use

  11/20/2020

  AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy (CRT) and previously treated advanced bladder cancer.

• AstraZeneca demonstrates strengths in haematology with robust data at ASH 2020

  11/19/2020

  AstraZeneca will present new research aimed at addressing key unmet needs facing patients with blood cancers at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held virtually from 5 to 8 December 2020.

• AstraZeneca Demonstrates Strength in Hematology With Robust Data at ASH 2020

  11/19/2020

  AstraZeneca Demonstrates Strength in Hematology With Robust Data at ASH 2020 Presentations support CALQUENCE efficacy and tolerability with long-term follow-up in mantle cell lymphoma and pooled safety data in chronic lymphocytic leukemia Emerging pipeline shows promise in novel targets and mechanisms to treat resistant and aggressive blood cancers

• Data from contemporary registry confirms that four out of five patients with heart failure with reduced ejection fraction eligible for treatment with FARXIGA

  11/13/2020

  TRANSLATE-HF study establishes the potential for broad use of the only SGLT2 inhibitor indicated in patients with heart failure with reduced ejection fraction with and without diabetes

• AstraZeneca Partners with CCT to Conduct COVID-19 Vaccine Clinical Trials in Arizona

  11/12/2020

  CCT Research  (CCT), a leader in community-based, embedded clinical research, today announced its partnership with AstraZeneca to advance COVID-19 research. Together with local healthcare providers, CCT will facilitate clinical trials for the AZD1222 C

• NYU Langone Health to Enroll Healthy Volunteers In Clinical Trial for COVID-19 Vaccine

  11/11/2020

  NYU Grossman School of Medicine is among the centers enrolling participants in a randomized phase 3 clinical trial to determine the safety and efficacy of the COVID-19 vaccine candidate developed by the pharmaceutical company AstraZeneca.

• Tezepelumab NAVIGATOR Phase III Trial Met Primary Endpoint of a Statistically Significant and Clinically Meaningful Reduction in Exacerbations in a Broad Population of Patients With Severe Asthma

  11/10/2020

  AstraZeneca and Amgen today announced positive results from the NAVIGATOR Phase III trial for the potential new medicine tezepelumab in patients with severe, uncontrolled asthma. NAVIGATOR met the primary endpoint with tezepelumab added to standard of care (SoC) demonstrating a statistically significant and clinically meaningful

• BRILINTA Approved in the US to Reduce the Risk of Stroke in Patients With an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

  11/6/2020

  AstraZeneca’s BRILINTA ® (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). The approva

• LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

  11/5/2020

  Patients Treated with LYNPARZA and Bevacizumab Lived Without Disease Progression or Death for a Median of 37.2 Months vs. 17.7 Months for Bevacizumab Alone Following Response to Platinum-Based Chemotherapy

• Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies

  11/2/2020

  Collaboration Combines Fusion's Targeted Alpha Therapies (TATs) Platform with AstraZeneca's Antibody and Oncology Portfolio to Create Novel Cancer Therapies

• DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy

  11/2/2020

  DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU ® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy

• FASENRA® eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial

  10/29/2020

  FASENRA ® eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial 62% of patients stopped OCS use in largest ever steroid sparing trial in severe asthma

• Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi® in Stage III NSCLC

  10/29/2020

  Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi ® in Stage III NSCLC - Collaboration Further Strengthens Arcus’s Position at the Forefront of the Anti-TIGIT Field and Leverages AstraZeneca’s Leadership in the Curative-Intent Stage III NSCLC Setting - Registrational Trial for Domvanalimab plus Imfinzi Expected to Begin in 2021 - Further Builds on the Arcus-Gilea

• ENHERTU (fam-trastuzumab deruxtecan-nxki) Granted Priority Review in the US For the Treatment of HER2-positive Metastatic Gastric Cancer

  10/28/2020

  Only HER2-directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for previously treated patients in this setting

• FARXIGA DAPA-CKD Phase III Trial Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal Death in Patients With Chronic Kidney Disease Irrespective of Underlying Cause

  10/23/2020

  FARXIGA DAPA-CKD Phase III Trial Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal Death in Patients With Chronic Kidney Disease Irrespective of Underlying Cause Results reinforce FARXIGA’s potential to treat a wide range of patients with chronic kidney disease WILMINGTON, Del.--( BUSINESS WIRE )-- A new subgroup analysis from the ground-breaking DAPA-CKD Phase III trial showed that AstraZeneca’s FARXIGA ® (dapagliflozin), on

• AstraZeneca Announces Winners and Recognizes Unsung Heroes of Oncology in 2020 Cancer Community (C2) Awards

  10/22/2020

  AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the second annual Cancer Community (C2) Awards. A part of the YOUR Cancer program, the C2 Awards celebrate grassroots organizations and individuals making impactful change in the cancer community.

• TAGRISSO Granted Priority Review in the US for the Adjuvant Treatment of Patients With Early-stage EGFR-mutated Lung Cancer

  10/20/2020

  AstraZeneca’s TAGRISSO ® (osimertinib) has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in the US for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated

• Advocates Stand Up Against AstraZeneca to Save Drug Discount Program for Vulnerable Populations

  10/13/2020

  Dozens of concerned healthcare advocates from across the northeast region protest AstraZeneca, one of five U.S. based pharmaceutical companies that have cut back on the number of drugs they provide through the 340B federal drug discount program.